Shares of Ultragenyx Pharmaceutical RARE were flat in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 42.35% over the past year to ($1.13), which beat the estimate of ($1.27).
Revenue of $81,470,000 up by 215.78% year over year, which beat the estimate of $53,890,000.
Looking Ahead
Ultragenyx Pharmaceutical hasn't issued any earnings guidance for the time being.
Revenue guidance hasn't been issued by the company for now.
Conference Call Details
Date: Oct 27, 2020
Time: 05:00 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/yvtmu8mm
Recent Stock Performance
52-week high: $99.25
52-week low: $31.99
Price action over last quarter: Up 24.67%
Company Description
Ultragenyx Pharmaceutical Inc is a US-based biopharmaceutical company. It identifies, acquires, develops, and commercialize novel products for the treatment of serious rare and ultra-rare diseases, with the focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
